Heart sphingolipids in health and disease

Advances in Experimental Medicine and Biology

Volumn 721, Issue , 2011, Pages 41-56

  Baranowski, Marcin ^a   Górski, Jan ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CERAMIDASE; CERAMIDE 1 PHOSPHATE; G PROTEIN COUPLED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 2; TROGLITAZONE;

ARTICLE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DRUG MECHANISM; ENZYME ACTIVITY; EXERCISE; GLUCOSE TRANSPORT; HEART DISEASE; HEART INFARCTION PREVENTION; HEART MUSCLE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INSULIN SENSITIVITY; LIPID ANALYSIS; LIPID COMPOSITION; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOTOXICITY; METABOLIC REGULATION; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REPERFUSION INJURY; SKELETAL MUSCLE; TISSUE DISTRIBUTION;

ANIMALS; CARDIOMYOPATHIES; CERAMIDES; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DISEASE MODELS, ANIMAL; EXERCISE; HEART FAILURE; HUMANS; LYSOPHOSPHOLIPIDS; MICE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RATS; RATS, ZUCKER; RECEPTORS, LYSOSPHINGOLIPID; SECOND MESSENGER SYSTEMS; SPHINGOLIPIDS; SPHINGOSINE;

ANIMALIA;

EID: 80053595895     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0650-1_3     Document Type: Article

References (70)

1. Okazaki T, Bielawska A, Bell RM et al. Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J Biol Chem 1990; 265:15823-31.
2. Yang J, Yu Y, Sun S et al. Ceramide and other sphingolipids in cellular responses. Cell Biochem Biophys 2004; 40:323-50.
3. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2005; 45:42-72. (Pubitemid 43170804)
4. Baranowski M, Zabielski P, Blachnio A et al. Effect of exercise duration on ceramide metabolism in the rat heart. Acta Physiol (Oxf) 2008; 192:519-29. (Pubitemid 351322720)
5. Baranowski M, Blachnio-Zabielska A, Hirnle T et al. Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide. J Lipid Res 2010; 51:74-80.
6. Li CM, Hong SB, KopalGet al. Cloning and characterization ofthe full-length cDNA and genomic sequences encoding murine acid ceramidase. Genomics 1998; 50:267-74. (Pubitemid 28303521)
7. Li CM, Park JH, He X et al. The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis and expression. Genomics 1999; 62:223-31. (Pubitemid 30053938)
8. Liu H, Sugiura M, Nava VE et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 2000; 275:19513-20. (Pubitemid 30441543)
9. Yang Q, Li Y. Roles of PPARs on regulating myocardial energy and lipid homeostasis. J Mol Med 2007; 85:697-706. (Pubitemid 47063523)
10. FinckBN, HanX, Courtois M et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis ofdiabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad SciUSA2003;100:1226-31. (Pubitemid 36183984)
11. Baranowski M, Blachnio A, Zabielski P et al. PPARalpha agonist induces the accumulation of ceramide in the heart ofrats fed high-fat diet. J Physiol Pharmacol 2007; 58:57-72. (Pubitemid 350021137)
12. Rivier M, Castiel I, Safonova I et al. Peroxisome proliferator-activated receptor-alpha enhances lipid metabolism in a skin equivalent model. J Invest Dermatol 2000; 114:681-7. (Pubitemid 30227000)
13. Bahr M, Spelleken M, Bock M et al. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia 1996; 39:766-74. (Pubitemid 26228105)
14. Sidell RJ, Cole MA, Draper NJ et al. Thiazolidinedione treatment normalizes insulin resistance and ischemic injuryinthe zuckerFattyratheart. Diabetes 2002; 51:1110-7. (Pubitemid 34438357)
15. Oakes ND, Kennedy CJ, Jenkins AB et al. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43:1203-10. (Pubitemid 24361185)
16. Carley AN, Semeniuk LM, Shimoni Y et al. Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am J Physiol Endocrinol Metab 2004; 286:E449-55. (Pubitemid 38292696)
17. Liu LS, Tanaka H, Ishii S et al. The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Endocrinology 1998; 139:4531-9. (Pubitemid 28487769)
18. Zhou YT, Grayburn P, Karim A et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97:1784-9. (Pubitemid 30118520)
19. Hanada K. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim Biophys Acta 2003; 1632:16-30. (Pubitemid 36628112)
20. Shimabukuro M, Higa M, Zhou YT et al. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J Biol Chem 1998; 273:32487-90. (Pubitemid 28557623)
21. Blazquez C, Geelen MJ, Velasco G et al. The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett 2001; 489:149-53. (Pubitemid 32126399)
22. Liu L, Shi X, Bharadwaj KG et al. DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem 2009; 284:36312-23.
23. Sabbadini RA, Danieli-Betto D, Betto R. The role of sphingolipids in the control of skeletal muscle function: a review. Ital J Neurol Sci 1999; 20:423-30.
24. Dobrzyn A, Gorski J. Effect of acute exercise on the content of free sphinganine and sphingosine in different skeletal muscle types of the rat. Horm Metab Res 2002; 34:523-9. (Pubitemid 35192240)
25. McDonough PM, Yasui K, Betto R et al. Control of cardiac Ca2+ levels. Inhibitory actions of sphingosine on Ca2+ transients and L-type Ca2+ channel conductance. Circ Res 1994; 75:981-9.
26. Sharma C, Smith T, Li S et al. Inhibition ofCa2+release channel (ryanodine receptor) activity by sphingolipid bases: mechanism of action. Chem Phys Lipids 2000; 104:1-11. (Pubitemid 29537680)
27. Dawson E, George K, Shave R et al. Does the human heart fatigue subsequent to prolonged exercise?. Sports Med 2003; 33:365-80 (Pubitemid 36560709)
28. Krown KA, Page MT, Nguyen C et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996; 98:2854-65.
29. Bielawska AE, Shapiro JP, Jiang L et al. Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol 1997; 151:1257-63. (Pubitemid 27479755)
30. Zhang DX, Fryer RM, Hsu AK et al. Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res Cardiol 2001; 96:267-74. (Pubitemid 32433061)
31. Cordis GA, Yoshida T, Das DK. HPTLC analysis of sphingomylein, ceramide and sphingosine in ischemic/ reperfusedratheart. JPharmBiomedAnal 1998; 16:1189-93. (Pubitemid 28141095)
32. Argaud L, Prigent AF, Chalabreysse L et al. Ceramide in the antiapoptotic effect ofischemic preconditioning. Am J Physiol Heart Circ Physiol 2004; 286:H246-51. (Pubitemid 38049486)
33. Beresewicz A, Dobrzyn A, Gorski J. Accumulation of specific ceramides in ischemic/reperfused rat heart; effect of ischemic preconditioning. J Physiol Pharmacol 2002; 53:371-82.
34. Hernandez OM, Discher DJ, Bishopric NH et al. Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ Res 2000; 86:198-204. (Pubitemid 30086181)
35. Jessup W. Lipid metabolism: sources and stability of plasma sphingosine-l-phosphate. Curr Opin Lipidol 2008; 19:543-4.
36. Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in cardioprotection. J Cardiovasc Pharmacol 2009; 53:189-97.
37. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 2009; 82:193-200.
38. Karliner JS, Honbo N, Summers K et al. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2001; 33:1713-7. (Pubitemid 32844228)
39. Lecour S, Smith RM, Woodward B et al. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34:509-18.
40. Jin ZQ, Zhou HZ, Zhu P et al. Cardioprotection mediated by sphingosine-l-phosphate and ganglioside GM- 1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 2002; 282:H1970-7. (Pubitemid 34663002)
41. Tao R, Zhang J, Vessey DA et al. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 2007; 74:56-63. (Pubitemid 46366955)
42. Vessey DA, Kelley M, Li L et al. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit 2006; 12:BR318-24. (Pubitemid 44556077)
43. Jin ZQ, Zhang J, Huang Y et al. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/ reperfusion injury. Cardiovasc Res 2007; 76:41-50. (Pubitemid 47362044)
44. Duan HF, Wang H, Yi J et al. Adenoviral gene transfer ofsphingosine kinase 1 protects heart against ischemia/ reperfusion-induced injury and attenuates its postischemic failure. Hum Gene Ther 2007; 18:1119-28. (Pubitemid 350114687)
45. Kennedy S, Kane KA, Pyne NJ et al. Targeting sphingosine-l-phosphate signalling for cardioprotection. Curr Opin Pharmacol 2009; 9:194-201.
46. Vessey DA, Li L, Kelley M et al. Sphingosine can pre and postcondition heart and utilizes a different mechanism from sphingosine 1-phosphate. J Biochem Mol Toxicol 2008; 22:113-8. (Pubitemid 351657194)
47. Zhang J, Honbo N, Goetzl EJ et al. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol 2007; 293:H3150-8. (Pubitemid 350106541)
48. Means CK, Xiao CY, Li Z et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007; 292:H2944-51. (Pubitemid 47084545)
49. Theilmeier G, Schmidt C, Herrmann J et al. High-density lipoproteins and their constituent, sphingosine-l-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006; 114:1403-9. (Pubitemid 44454560)
50. Hofmann U, Burkard N, Vogt C et al. Protective effects of sphingosine-l-phosphate receptor agonist treatment aftermyocardial ischaemia-reperfusion. Cardiovasc Res 2009; 83:285-93.
51. TsukadaYT, SannaMG,RosenHet al. SIPl-selectiveagonistSEW2871 exacerbatesreperfusionarrhythmias. J Cardiovasc Pharmacol 2007; 50:660-9.
52. JinZQ, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 2004; 110:1980-9. (Pubitemid 39331911)
53. Vessey DA, Li L, Honbo N et al. Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre and postconditioning. Am J Physiol Heart Circ Physiol 2009; 297:H1429-35.
54. JinZQ, Karliner JS, Vessey DA. Ischaemicpostconditioningprotects isolatedmousehearts against ischaemia/ reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res 2008; 79:134-40. (Pubitemid 351881933)
55. Knapp M, Baranowski M, Czarnowski D et al. Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. Med Sci Monit 2009; 15:CR490-3.
56. Borradaile NM, Schaffer JE. Lipotoxicity in the heart. Curr Hypertens Rep 2005; 7:412-7. (Pubitemid 43136936)
57. Harmancey R, Wilson CR, Taegtmeyer H. Adaptation and maladaptation ofthe heart in obesity. Hypertension 2008; 52:181-7.
58. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 2002; 105:1861-70. (Pubitemid 34408899)
59. Park TS, Yamashita H, Blaner WS et al. Lipids in the heart: a source of fuel and a source of toxins. Curr Opin Lipidol 2007; 18:277-82. (Pubitemid 46743051)
60. Chiu HC, Kovacs A, Ford DA et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001; 107:813-22. (Pubitemid 32274034)
61. Chiu HC, Kovacs A, Blanton RM et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005; 96:225-33. (Pubitemid 40209370)
62. Yagyu H, Chen G, Yokoyama M et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 2003; 111:419-26. (Pubitemid 36182219)
63. Son NH, Park TS, Yamashita H et al. Cardiomyocyte expression ofPPARgamma leads to cardiac dysfunction in mice. J Clin Invest 2007; 117:2791-801. (Pubitemid 47529610)
64. Park TS, Hu Y, Noh HL et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008; 49:2101-12.
65. Basu R, Oudit GY, Wang X et al. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 2009; 297:H2096-108.
66. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest 2005; 115:565-71. (Pubitemid 40322226)
67. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115:3213-23. (Pubitemid 47012236)
68. Dyntar D, Eppenberger-Eberhardt M, Maedler K et al. Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 2001; 50:2105-13. (Pubitemid 33643679)
69. Hickson-Bick DL, Buja ML, McMillin JB. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J Mol Cell Cardiol 2000; 32:511-9.
70. Torre-Villalvazo I, Gonzalez F, Aguilar-Salinas CA et al. Dietary soy protein reduces cardiac lipid accumulation and the ceramide concentration in high-fat diet-fed rats and ob/ob mice. J Nutr 2009; 139:2237-43.